Brandon Bernard

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Anis Hamid, Kathryn P. Gray, Grace Shaw et al. · European Urology · 2018 · 269 citations

Medicine, Molecular Genetics, Oncology +16

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Edoardo Francini, Kathryn P. Gray, Wanling Xie et al. · The Prostate · 2018 · 198 citations · Full text

Medicine, Oncology, Urology +14

Genomic evolution and chemoresistance in germ-cell tumours

Amaro Taylor‐Weiner, Travis Zack, Elizabeth O’Donnell et al. · Nature · 2016 · 170 citations · Full text

Life Sciences, Genetics, Oncology +14

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

Vitaly Margulis, Mäneka Puligandla, Edouard J. Trabulsi et al. · The Journal of Urology · 2019 · 133 citations · Full text

Medicine, Oncology, Urology +16

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry

Richard Cathomas, Dirk Klingbiel, Brandon Bernard et al. · Journal of Clinical Oncology · 2018 · 76 citations · Full text

Medicine, Nuclear Medicine, Oncology +17